Long-term cholinesterase inhibitor treatment of Alzheimer's disease

CNS Drugs
Peter Johannsen

Abstract

The most prevalent cause of dementia--Alzheimer's disease--is characterised by an early cholinergic deficit that is in part responsible for the cognitive deficits, especially memory and attention defects, seen with this condition. Three cholinesterase inhibitors (ChEIs), namely donepezil, rivastigmine and galantamine, are widely used for the symptomatic treatment of patients with Alzheimer's disease. Placebo-controlled, randomised clinical trials have shown significant effects of these drugs on global function, cognition, activities of daily living (ADL) and behavioural symptoms in patients with this disorder. These trials have been conducted for up to 12 months and were followed by open-label extension studies. One placebo-controlled, randomised clinical trial followed patients for up to 4 years. Both retrospective and prospective follow-up studies suggest a treatment effect for ChEIs that lasts for up to 5 years. Studies have shown comparable effects for ChEIs in patients with moderate-to-severe Alzheimer's disease or mild Alzheimer's disease. Clinically relevant responses consist not only of improvement over 3-6 months but also stabilisation and possibly slower than expected decline. Lack of overt clinical improvement in one...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Nov 1, 1984·The American Journal of Psychiatry·W G RosenK L Davis
Apr 24, 1999·BMJ : British Medical Journal·T Bayer
Apr 24, 1999·BMJ : British Medical Journal·A Berger
May 15, 1999·Dementia and Geriatric Cognitive Disorders·A BurnsL T Friedhoff
Feb 24, 2001·Journal of Psychopharmacology·N R DunnS A Shakir
May 15, 2001·Dementia and Geriatric Cognitive Disorders·R S DoodyP Massman
Jun 20, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·H J TschampaS Poser
Jul 24, 2001·International Journal of Geriatric Psychiatry·B WinbladD Wilkinson
Aug 15, 2001·Neurology·B WinbladUNKNOWN Donepezil Nordic Study Group
Aug 29, 2001·Neurology·H FeldmanUNKNOWN Donepezil MSAD Study Investigators Group
Aug 7, 2002·Clinical Pharmacokinetics·Michael W JannGary W Small
Nov 29, 2002·Journal of Neural Transmission. Supplementum·H GeertsA Spiros
Feb 5, 2003·Dementia and Geriatric Cognitive Disorders·Rafael BlesaSusanne Schwalen
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Marek SamochockiAlfred Maelicke
Jul 24, 2003·Drugs & Aging·Gordon WilcockUNKNOWN GAL-GBR-2 Study Group
Oct 18, 2003·Dementia and Geriatric Cognitive Disorders·Zakiya J Wynn, Jeffrey L Cummings
Jun 29, 2004·Lancet·Lon S Schneider

❮ Previous
Next ❯

Citations

Aug 30, 2013·Journal of Medicinal Chemistry·C David AnderssonAnna Linusson
Apr 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yukiko YoshidaTsunehiko Ikeda
Sep 30, 2005·Dementia and Geriatric Cognitive Disorders·Gustavo C RománRachel J Schindler
Feb 22, 2007·Dementia and Geriatric Cognitive Disorders·Asa K WallinUNKNOWN Swedish Alzheimer Treatment Study Group
Oct 12, 2007·CNS Drugs·Lily P H Yang, Gillian M Keating
Jan 28, 2005·Postgraduate Medicine·Sandra E Black
Dec 24, 2005·Expert Opinion on Investigational Drugs·Ana Martinez, Ana Castro
Feb 4, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Gülhan Turan-ZitouniGülşen Akalın Çiftçi
Sep 13, 2011·Neurología : publicación oficial de la Sociedad Española de Neurología·J L MolinuevoUNKNOWN Grupo de Trabajo del Estudio TRACE
Aug 15, 2008·Bioorganic & Medicinal Chemistry·Xiang ZhouLing-Yi Kong
Oct 19, 2011·Archiv der Pharmazie·Mehlika Dilek AltintopGülşen Akalın
Jul 25, 2013·Archiv der Pharmazie·Mehlika D AltıntopZafer A Kaplancıklı
Sep 27, 2005·Bioorganic & Medicinal Chemistry·María Isabel Rodríguez-FrancoAna Martínez
Oct 23, 2014·Archives of Pharmacal Research·So-Hyeon AhnByung-Joo Park
Oct 30, 2014·Journal of Computer-aided Molecular Design·C David AnderssonAnna Linusson
Sep 1, 2005·Clinical EEG and Neuroscience·Robert SneddonUtpal Saha
Nov 25, 2005·Journal of Geriatric Psychiatry and Neurology·Linda ErcoliLissy F Jarvik
Feb 16, 2006·Clinical EEG and Neuroscience·Robert SneddonUtpal Saha
Jul 8, 2009·International Journal of Molecular Sciences·Yahya E ChoonaraSibongile R Sibambo
Apr 4, 2014·Chemical & Pharmaceutical Bulletin·Xiao-jian XueWen-long Huang
Oct 11, 2005·The Journal of Pharmacology and Experimental Therapeutics·C M HernandezA V Terry
Oct 3, 2020·Bioorganic & Medicinal Chemistry·Priyanka Kumari ChoubeySushant Kumar Shrivastava

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.